For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 12,606 | |||
| General and administrative | 13,969 | |||
| Operating loss | -26,575 | |||
| Interest expense | 207 | |||
| Interest income and other income (expense), net | 520 | |||
| Other income (expense), net | 313 | |||
| Provision for income taxes | 0 | |||
| Net loss | -26,262 | |||
| Basic EPS | -6.33 | |||
| Diluted EPS | -6.33 | |||
| Basic Average Shares | 4,149,733 | |||
| Diluted Average Shares | 4,149,733 | |||
Tempest Therapeutics, Inc. (TPST)
Tempest Therapeutics, Inc. (TPST)